This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Focus on Childhood and Adolescent Mental Health

One-Year Course and Predictors of Outcome of Adolescent Depression: A Case-Control Study in Finland

Linnea Karlsson, MD, PhD; Olli Kiviruusu, BSocSc; Jouko Miettunen, PhD; Hannele Heilä, MD, PhD; Matti Holi, MD, PhD; Titta Ruuttu, MA; Virpi Tuisku, MSocSc; Mirjami Pelkonen, PhD; and Mauri Marttunen, MD, PhD

Published: May 11, 2008

Article Abstract

Background: Clinical studies on the outcome of adolescent depression beyond treatment trials are scarce.

Objective: To investigate the impact of characteristics of the depressive episode and current comorbidity on the 1-year outcome of depression.

Method: A sample of 174 consecutive adolescent psychiatric outpatients (aged 13 through 19 years) and 17 school-derived matched controls, all with unipolar depressive disorders at baseline, were reinterviewed for DSM-IV Axis I and Axis II disorders at 12 months. The study was conducted between January 1998 and May 2002.

Results: The outpatients had equal recovery rate and episode duration but shorter time to recurrence than the controls. Among the outpatients, Axis II comorbidity predicted shorter time to recurrence (p = .02). Longer time to recovery was predicted by earlier lifetime age at onset for depression (p = .02), poor psychosocial functioning (p = .003), depressive disorder diagnosis (p <= .05), and longer episode duration by study entry (p = .001), with an interaction between episode duration and depressive disorder diagnosis (p = .04).

Conclusions: Characteristics of depression generally predicted the outcome better than comorbidity. Axis II comorbidity has prognostic value in adolescent depression.

Volume: 69

Quick Links: Child and Adolescent , Populations

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...